Mortalidade de indivíduos idosos cardíacos tratados com digoxina

Edivaldo Cremer, Almir Conrrado Rodrigues de Lima, Larissa Laila Cassarotti, Gabrielle Rodrigues Munhoz, Romulo Jordão Barbosa Pedrinho, Roberto Kenji Nakamura Cuman

Resumo

Objetivou-se descrever as taxas de mortalidade e sobrevida de idosos com insuficiência cardíaca que fizeram uso de digoxina, bem como identificar os fatores de risco associados à mortalidade. Prontuários de pacientes idosos (≥60 anos) atendidos no ambulatório de cardiologia para insuficiência cardíaca e que fizeram uso de digoxina foram triados e selecionados para este estudo retrospectivo. Variáveis sociodemográficas e clínicas foram mensuradas. A sobrevida foi verificada pelas curvas de Kaplan-Meier e teste log-rank. A regressão logística múltipla ajustada foi utilizada para avaliar os potenciais fatores de risco associados à mortalidade. Dos 65 prontuários analisados a sobrevida foi menor nos pacientes que utilizavam a dosagem de 0,125mg (p=0,093). A taxa de mortalidade foi de 35,9% e as chances de óbitos aumentaram nos indivíduos com idade acima de 76 anos (p=0,010; ORaj: 4,021), que possuíam outras doenças cardíacas (p=0,004; ORaj: 5,943) e com maior tempo de uso da digoxina (p=0,047; ORaj: 1,164).

Descritores: Digoxina, Mortalidade, Idoso.

 

Mortality of digoxin-treated elderly cardiac subjects

Abstract: This study aimed to describe the mortality and survival rates of elderly with heart failure who used digoxin, as well as to identify the risk factors associated with mortality. Records of elderly patients (≥60 years old) treated at the heart failure outpatient cardiology clinic were screened and selected for this retrospective study. Sociodemographic and clinical variables were measured. Survival was verified by Kaplan-Meier curves and log-rank test. Adjusted multiple logistic regression was used to assess potential risk factors associated with mortality. Of the 65 medical records analyzed, survival was lower in patients using 0.125 mg (p=0.093). The mortality rate was 35.9% and the chances of death increased in individuals over the age of 76 years (p=0.010; ORaj: 4.021), who had other heart disease (p=0.004; ORaj: 5.943) and with longer use of digoxin (p=0.047; ORaj: 1.164).

Descriptors: Digoxin, Mortality, Aged.

 

Mortalidad de ancianos cardiacos tratados con digoxina

Resumen: El objetivo es describir las tasas de mortalidad y supervivencia de personas mayores con insuficiencia cardíaca que usaban digoxina, así como identificar los factores de riesgo asociados con la mortalidad. Los registros de pacientes ancianos (≥60 años de edad) tratados en la clínica ambulatoria de cardiología con insuficiencia cardíaca se examinaron para este estudio retrospectivo. Se midieron variables sociodemográficas y clínicas. La supervivencia se verificó mediante curvas de Kaplan-Meier y prueba de log-rank. Se utilizó la regresión logística múltiple ajustada para evaluar los posibles factores de riesgo asociados con la mortalidad. De los 65 registros médicos analizados, la supervivencia fue menor en los pacientes que utilizaron 0.125 mg (p=0.093). La tasa de mortalidad fue de 35.9% y las posibilidades de muerte aumentaron en personas mayores de 76 años (p=0.010; ORaj: 4.021), que tenían otras enfermedades cardíacas (p=0.004; ORaj: 5.943) y con uso más prolongado de digoxina (p=0.047; ORaj: 1.164).

Descriptores: Digoxina, Mortalidad, Anciano.

Texto completo:

PDF

Referências

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2016; 37:2893-962.

McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012; 14:803-69.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. ACCF/ AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62:e147-e239.

Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993; 22:955-62.

Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993; 329:1-7.

Garg R, Gorlin R, Smith T, Yusuf S, The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336:525-33.

Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015; 36(28):1831-8.

Martin-Suarez A, García González D, Macías Núñez JF, Ardanuy Albajar R, Calvo Hernández MV. A new method for individualized digoxin dosing in elderly patients. Drugs Aging. 2016; 33(4):277-84.

Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes. 2013; 6:525-33.

Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, et al. Increased mortality among patients taking digoxin--analysis from the AFFIRM study. Eur Heart J. 2013; 34:1481-88.

Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014; 64:660-8.

Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Behlouli H, Pilote L. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart failure. Am J Cardiol. 2014; 114:401-6.

Gamst J, Christiansen CF, Rasmussen BS, Rasmussen LH, Thomsen RW. Pre-existing atrial fibrillation and risk of arterial thromboembolism and death following pneumonia: a population-based cohort study. BMJ Open. 2014; 4:e006486.

Freeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK, et al. Digoxin and risk of death in adults with atrial fibrillation: The ATRIA-CVRN Study. Circ Arrhythm Electrophysiol. 2015; 8:49-58.

Pastori D, Farcomeni A, Bucci T, Cangemi R, Ciacci P, Vicario T, et al. Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. Int J Cardiol. 2015; 180:1-5.

Domanski M, Fleg J, Bristow M, Knox S. The effect of gender on outcome in digitalistreated heart failure patients. J Card Fail. 2005; 11:83-6.

Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, et al. ARISTOTLE Committees and Investigators. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 201813; 71(10):1063-74.

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41.

Romão Junior JE. Doença Renal Crônica: Definição, Epidemiologia e Classificação. Braz. J. Nephrol. 2004; 26(Suppl 1):1-3.

Adams Jr KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005; 149:209-216.

Hauptman P, Kelly RA. Digitalis. Circulation. 1999; 99:1265-70.

Ahmed A. Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. J Gerontol A Biol Sci Med Sci. 2007; 62:323-9.

Bocchi EA, Marcondes-Braga FG, Ayub-Ferreira SM, Rohde LE, Oliveira WA, Almeida DR, et al. Sociedade Brasileira de Cardiologia. III Diretriz Brasileira de Insuficiência Cardíaca Crônica. Arq Bras Cardiol. 2009; 93(supl 1):28-9.

Hood WB Jr, Dans AL, Guyatt GH, Jaeschke R, McMurray JJ. Digitalis for treatment of heart failure in patients in sinus rhythm. Cochrane Database Syst Rev. 2014; (4):CD002901.

Figueiredo EL, Machado FP. Os papéis da digoxina em pacientes com insuficiência cardíaca uma revisão geral. Insuf Card. 2010; (5):72-8.


Visualizações do PDF:

13 views


Visualizações do Resumo:

176 views

Apontamentos

  • Não há apontamentos.
Copyright: ©-2014 Revista Recien - Revista Científica de Enfermagem. Todos os direitos reservados.
Tema: Mason Publishing Group. Customizado por: Articloud